Lupin is expected to report continued weakness in its US business due to higher competition in its large generic products. We expect 5% yoy growth in revenue while EBITDA and PAT are expected to decline 29% and 37% yoy, respectively.
from India Infoline News Service https://ift.tt/2qkawG6
No comments:
Post a Comment